Cargando…
MYL-1402O: A Bevacizumab Biosimilar
MYL-1402O (Abevmy(®), Lextemy(®)) is a biosimilar of the reference anti-vascular endothelial growth factor antibody bevacizumab. Abevmy(®) is approved for use in all indications for which reference bevacizumab is approved, including the treatment of non-small cell lung cancer (NSCLC) and other solid...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015968/ https://www.ncbi.nlm.nih.gov/pubmed/34910269 http://dx.doi.org/10.1007/s11523-021-00858-7 |